Member Info for chrishutch

This week's climber?

I had a chilled weekend so I didn't notice twitter was full of very positive-sounding tweets about the company. As well as reading and trying to work out the connections, NHS, CBD, cloud storage, rinodrive etc.

It was also Gerard Brandon's birthday!
-Happy Birthday!

Great article there as always Elrico. If you are not following @LEMMINGINVESTOR you should be.

Yes, it is fair to mention, as ZOE was formally known HNR has a two year agreement with SKIN Integumen to provide hemp-derived CBD grown under quality-controlled conditions, with less than 0.2% THC, to Cellulac plc (9.35% owned by Integumen plc) for conversion to medical grade CBD. This will then be incorporated into, and tested on, Integumen plc's CBD infused wound care "Wound pHase" and STOER range of skincare products.

Under the agreement, Highlands will supply CBD to Cellulac for the conversion into medical grade CBD, who will then submit the finished products to Integumen's Labskin test facilities. The CBD will be infused on to Integumen's WoundpHase and STOER range of wound care and skin care products, providing a vertically integrated farm-to-finished product.

Gerard Brandon - CEO of Integumen, comments:

"We are delighted to to be part of this agreement with Highlands. To satisfy regulatory authorities in multiple jurisdictions, it is necessary to identify the origin of each plant and confirm the supervised growth from seed, extraction and shipment. The CBD market is still evolving, so it is imperative that any CBD infused treatments in wound care and skin care are subject to the highest testing standards, scientific verification and validation prior to product launch."

I imagine this a mutually attractive agreeement. As business generation could flow both ways.

As I have said before there is a lot of Integumens products and services that rarely get a mention. Some of which already generating revenue streams. There is the STOER range and the Woundcare Range as well as the close to 10% ownership of Cellulac.

Did the same yesterday moved down a little and then climbed higher so don't rule out a positive day here. Still looks very bullish. The pullbacks enable new investors to join us on this journey.

Also a little bullish divergence on the daily chart. So we still might be off to the races.

Apologies for the duplication in my post, over-excited with progress.

https://www.proactiveinvestors.co.uk/companies/news/906522/integumen-agrees-three-new-rd-deals-with-top-20-global-cosmetic-firms-906522.html

Just listened.. to proactive vid. Love that he says we have just opened larger lab space (3 times bigger than previous) but because growth is so great, we have just taken an option for another 3000 square ft.

Also, note that they are on target to reach year-end even with the delay to lab space. And.... that you can tell that 2020 is going to be a huge growth year for the company. When you look at the achievements this company has made this year it is truly remarkable. Maybe I will stick some bullet points together, to sum up, the journey but really it is a wow year for the company and by the sounds of it.............. next year will be equally as impressive. 'Very good position, it's a wonderful growth story"

And 3 new research and development clients. Two completely new and one existing,

I note he said that the company can now provide the option to look at three types of test,
1. healthy skin
2. diseased skin
3. a variable that allows the company to test how long it takes to move from diseased skin to a healthy skin balance.

Companies are now not only testing new products but also testing what happens to existing products when a single ingredient is added in. My god the upscale ability of testing 'adding in a single ingredient' could be huge. Just think how many times you see, 'new and improved' or 'with added' on labels.

Laughed when he said we have changed the claim from the top ten companies to the top 20 to avoid identifying them as subject to NDA.

When you look at the achievements this company has made this year it is truly remarkable. Maybe I will stick some bullet points together, to sum up, the journey but really it is a wow year for the company and by the sounds of next year will be equally as impressive. 'Very good position, it's a wonderful growth story"

Not only is the news flow really something but the chart is pointing to a bigger move up too. No doubt the rest of retail traders will figure out the potential here when we are a lot higher and sitting pretty.

decent buying - I have not had a chance to play video yet. Is it good?

Me too James. The company is making leaps and bounds.

Strangely the share price did the same last time there was news, shook a few out, made it difficult to buy and then video interview and up it went.

https://twitter.com/gjbrandon

Photos of new labs for those that are interested.

Gerard J Brandon
@gjbrandon
·
20m
Just arriving at #Labskin facility. Will catch up later with more news

thanks James. Odd that you are offered stock and I am not and also no trades for 40 minutes. I think there might be a delayed trade or something in the background here. I

Can anyone get a quote to buy?

won't quote me on a bean

Love this tweet

still Bullish on #SKIN as it moves like a Dinosaur in a symmetrical triangle.
https://twitter.com/Borg74/status/1192145519801491463?s=20

You can tell this company is going to be really big or taken out at some point. It is rubbing shoulders with the heavyweights and that is truly impressive.

RNS Number : 5291S
Integumen PLC
07 November 2019

AIM share code: SKIN
7 November 2019
Integumen PLC

("Integumen" or "Company")

3,000 square foot Labskin laboratories officially opened

Microbiome and Labskin clone R&D agreements signed with three Top 20 cosmetic companies

Integumen announces that its Labskin subsidiary has signed agreements with two new, and one existing, Top 20 global cosmetic company clients for microbiome research and development ("R&D") services, worth an aggregated low six-figure value, to be completed over the next four months. Additional R&D service agreements from all three clients are expected to follow on after these initial trials are completed.

Under the agreements, the Company will provide the first commercially available combination of cloned Labskin, microbiome tests and gene sequencing using data analytics on the LabskinAI platform. These are expected to confirm the impact of our clients' new products and ingredients on human skin. This extends the range of test services to include R&D support services, making full use of the Labskin healthy and diseased living skin models, at our newly enlarged laboratories in York, UK.

Gerard Brandon, CEO of Integumen plc, comments:

"We are delighted to open our new enlarged facilities in York and with the addition of three new R&D agreements, we remain on track to exceed £1m revenue by our year end. These new R&D contracts are in addition to product test services, and illustrate the demand for the full range of Labskin services and the progress we have made over the past 18 months. Each breakthrough and combination of cloned skin, microbiome definition for diseased skin and the data analytic use of AI on the gene sequencing results, without any harm to animals, builds the unique offering of the enlarged Group. This is why we believe that providing world class services to our prestigious client base in the skin care and cosmetic industries will continue to provide strong growth and new contract revenues into 2020, and ultimately, drive value for our shareholders."

YESSSS! Great news! better than expected. By the way, moneyman thank you for the compliment but I simply have a buy and hold position!

Positive news and a positive chart !

wow yes! primed for the morning!

:-)